Abstract
Elevated tumor necrosis factor (TNF)-alpha levels are associated with poor prognosis in patients with multiple myeloma (MM). Enbrel is a TNF antagonist fusion protein consisting of the extracellular, ligand-binding domain of the human p75 TNF receptor linked to the Fc portion of human IgG1. Ten patients with refractory MM were treated with Enbrel 25mg s.c twice weekly for a minimum of eight median age was 63 years (range, 43-76). The total number of Enbrel doses was 191 (median 16; range, 3-55). TNF alpha plasma levels increased significantly during treatment with Enbrel. No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Disease Progression
-
Drug Resistance, Neoplasm
-
Endothelial Growth Factors / blood
-
Etanercept
-
Female
-
Hepatocyte Growth Factor / blood
-
Humans
-
Immunoglobulin G / therapeutic use*
-
Intercellular Signaling Peptides and Proteins / blood
-
Interleukin-6 / blood
-
Lymphokines / blood
-
Male
-
Middle Aged
-
Multiple Myeloma / blood
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / pathology
-
Neoplasm Proteins / analysis*
-
Pilot Projects
-
Receptors, Tumor Necrosis Factor / therapeutic use*
-
Salvage Therapy
-
Treatment Failure
-
Tumor Necrosis Factor-alpha / analysis*
-
Vascular Endothelial Growth Factor A
-
Vascular Endothelial Growth Factors
Substances
-
Endothelial Growth Factors
-
Immunoglobulin G
-
Intercellular Signaling Peptides and Proteins
-
Interleukin-6
-
Lymphokines
-
Neoplasm Proteins
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Vascular Endothelial Growth Factor A
-
Vascular Endothelial Growth Factors
-
Hepatocyte Growth Factor
-
Etanercept